MD
Open
$0.28
Prev. Close
$0.28
High
$0.28
Low
$0.28
Market Snapshot
$7.25M
-0.2
-1.07
16
Medicus Pharma Ltd. is a biotech life sciences company, which focuses on accelerating the clinical development programs of novel and disruptive therapeutic assets. The company is headquartered in Conshohocken, Pennsylvania. The company went IPO on 2023-10-11. SkinJect Inc., a wholly owned subsidiary of the Company, is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver a chemotherapeutic agent to eradicate tumors cells. The company is conducting a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) in the United States and Europe. The company has also commenced a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-004) in the UAE. Its subsidiary, Antev Limited, is a late clinical stage biotech company, developing Teverelix, a GnRH antagonist, as a first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse episodes due to enlarged prostate.
emptyResult
Medicus Pharma Ltd. is a biotech life sciences company, which focuses on accelerating the clinical development programs of novel and disruptive therapeutic assets. The company is headquartered in Conshohocken, Pennsylvania. The company went IPO on 2023-10-11. SkinJect Inc., a wholly owned subsidiary of the Company, is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver a chemotherapeutic agent to eradicate tumors cells. The company is conducting a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) in the United States and Europe. The company has also commenced a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-004) in the UAE. Its subsidiary, Antev Limited, is a late clinical stage biotech company, developing Teverelix, a GnRH antagonist, as a first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse episodes due to enlarged prostate.
Recently from Cashu
Please provide the content you'd like me to summarize, and I'll create the appropriate title for you.
Please provide the text you would like to be summarized, and I will create a 300-word paragraph based on that information.
It seems there was no content provided for me to summarize. Please share the text you would like to be condensed, and I'll help you create a suitable title!
Please provide the text you would like to be summarized, and I will create the article based on that information.
Medicus Pharma's SKNJCT-003 Phase 2 Trial Reveals Promising Outcomes for New Treatment
Medicus Pharma's Breakthrough in Clinical Trials for SKNJCT-003: A New Hope in Treatment Options Medicus Pharma Ltd. announces a significant milestone in its clinical research endeavors with the topli…
Sure! Please share the content that you would like me to summarize, and I'll create a title for you.
Please provide the content you would like me to summarize, and I'll create a summary for you.